Mylan - MYL Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: NaN
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$0.00 As of 02/10/2021 01:00 AM ET

+0 (0.00%)

Get New Mylan Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MYL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYL

^$0.00

This price target is based on 0 analysts offering 12 month price targets for Mylan in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Mylan. This rating has held steady since October 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/9/2021

0 strong buy ratings
1 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/8/2021

0 strong buy ratings
0 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/6/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/4/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/4/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/3/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/1/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/1/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/28/2020	Wells Fargo & Company	Lower Target	Equal Weight	$17.00 ➝ $16.00	Medium
9/8/2020	Raymond James	Reiterated Rating	Buy		High
8/11/2020	UBS Group	Boost Target	Neutral	$17.00 ➝ $18.00	Medium
5/13/2020	UBS Group	Boost Target	Neutral	$16.00 ➝ $17.00	High
5/12/2020	Royal Bank of Canada	Reiterated Rating	Buy	$26.00	High
4/30/2020	Wells Fargo & Company	Lower Target	Equal Weight	$23.00 ➝ $18.00	Low
4/15/2020	Piper Sandler	Lower Target	Neutral	$23.00 ➝ $17.00	Low
4/2/2020	Morgan Stanley	Lower Target	Equal Weight	$23.00 ➝ $18.00	High
3/27/2020	Royal Bank of Canada	Lower Target	Outperform	$27.00 ➝ $26.00	Low
2/5/2020	SunTrust Banks	Reiterated Rating	Buy	$27.00	Medium
1/9/2020	Piper Sandler	Initiated Coverage	Neutral	$21.00	Medium
1/6/2020	Royal Bank of Canada	Boost Target	Outperform	$25.00 ➝ $27.00	High
12/16/2019	Evercore ISI	Reiterated Rating	Buy		Medium
11/27/2019	Cfra	Upgrade	Hold		Low
11/7/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal	$25.00 ➝ $18.00	Low
11/5/2019	Cfra	Downgrade	Hold ➝ Sell		High
9/12/2019	SunTrust Banks	Boost Target	Buy	$25.00 ➝ $27.00	Low
8/9/2019	Evercore ISI	Reiterated Rating	Buy		N/A
7/31/2019	Citigroup	Set Target	Buy	$26.00	Low
7/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$34.50	Low
7/30/2019	Mizuho	Boost Target	Neutral	$25.00 ➝ $27.00	Low
7/30/2019	Morgan Stanley	Reiterated Rating	Overweight	$22.00 ➝ $25.00	Low
7/19/2019	Wolfe Research	Initiated Coverage	Outperform ➝ Outperform	$27.00	Low
7/15/2019	Morgan Stanley	Set Target	Buy	$22.00	Low
6/12/2019	Cantor Fitzgerald	Lower Target	Neutral	$31.00 ➝ $18.00	Low
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$26.00	Medium
5/28/2019	UBS Group	Lower Target	Neutral	$23.00	Low
5/14/2019	Mizuho	Reiterated Rating	Hold		Medium
5/8/2019	Morgan Stanley	Set Target	Buy	$32.00	Medium
5/8/2019	Raymond James	Set Target	Buy	$31.00	Medium
5/8/2019	BMO Capital Markets	Set Target	Buy	$36.00	Medium
5/8/2019	Royal Bank of Canada	Lower Target	Outperform	$26.00	Low
5/7/2019	Wells Fargo & Company	Downgrade	Outperform ➝ Market Perform	$33.00 ➝ $22.00	Low
4/1/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High
3/27/2019	Argus	Lower Target	Buy	$32.00	Medium
3/19/2019	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$35.00	Low
3/7/2019	UBS Group	Reiterated Rating	Neutral	$31.00	Low
3/6/2019	Credit Suisse Group	Reiterated Rating	Buy	$37.00	Low
3/6/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$35.00	Medium
2/27/2019	Wells Fargo & Company	Lower Target	Outperform	$40.00 ➝ $33.00	High
2/27/2019	BTIG Research	Lower Target	Buy	$35.00	High
2/27/2019	BMO Capital Markets	Boost Target	Outperform	$40.00	High
2/27/2019	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$33.00	High
1/31/2019	Mizuho	Reiterated Rating	Neutral		High
1/23/2019	UBS Group	Downgrade	Buy ➝ Neutral	$54.00 ➝ $32.00	Medium
11/20/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	Low
11/15/2018	Argus	Upgrade	Hold ➝ Buy	$42.00	Medium
11/6/2018	JPMorgan Chase & Co.	Set Target	Buy	$45.00	Low
11/6/2018	Wells Fargo & Company	Upgrade	Market Perform ➝ Buy	$40.00	High
11/6/2018	Royal Bank of Canada	Lower Target	Outperform ➝ Buy	$51.00 ➝ $50.00	High
11/6/2018	Morgan Stanley	Boost Target	Equal Weight ➝ Hold	$36.00 ➝ $39.00	High
11/6/2018	Citigroup	Lower Target	Buy ➝ Buy	$48.00 ➝ $44.00	High
11/6/2018	Cowen	Set Target	Hold	$31.00	High
11/6/2018	Bank of America	Upgrade	Neutral ➝ Buy	$44.00 ➝ $42.00	High
11/5/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High
10/9/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$46.00 ➝ $36.00	Low
10/5/2018	Mizuho	Downgrade	Buy ➝ Neutral		Low
8/24/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low
8/15/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
8/13/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$53.00	Low
8/9/2018	Citigroup	Lower Target	Buy ➝ Buy	$50.00 ➝ $48.00	High
8/9/2018	SVB Leerink	Lower Target	Outperform	$53.00 ➝ $47.00	High
8/9/2018	Raymond James	Downgrade	Strong-Buy ➝ Outperform		High
8/9/2018	Cowen	Reiterated Rating	Hold	$31.00	High
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High
8/8/2018	Wells Fargo & Company	Set Target	Hold	$41.00	High
8/8/2018	Mizuho	Reiterated Rating	Buy	$54.00	High
8/2/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
7/25/2018	Wells Fargo & Company	Reiterated Rating	Hold		Medium
6/29/2018	Cantor Fitzgerald	Set Target	Hold	$41.00	Medium
6/14/2018	Guggenheim	Reiterated Rating	Buy	$59.00	Medium
6/6/2018	Guggenheim	Reiterated Rating	Buy	$59.00	Medium
5/31/2018	Wells Fargo & Company	Set Target	Market Perform ➝ Hold	$43.00 ➝ $41.00	High
5/29/2018	Bank of America	Lower Target	Neutral ➝ Neutral	$43.00 ➝ $42.00	Medium
5/23/2018	JPMorgan Chase & Co.	Set Target	Buy	$53.00	Low
5/9/2018	Cantor Fitzgerald	Set Target	Hold	$41.00	Low
4/23/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
4/12/2018	JPMorgan Chase & Co.	Set Target	Buy	$53.00	Low
4/12/2018	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$44.00	Low
4/11/2018	Cantor Fitzgerald	Set Target	Hold	$41.00	Medium
4/9/2018	Morgan Stanley	Set Target	Buy	$50.00	High
4/3/2018	Royal Bank of Canada	Set Target	Hold	$45.00	Low
3/15/2018	Mizuho	Boost Target	Buy	$45.00 ➝ $51.00	Low
3/6/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$39.00 ➝ $50.00	Medium
3/1/2018	UBS Group	Set Target	Buy	$54.00	High
3/1/2018	Cantor Fitzgerald	Set Target	Hold	$41.00	Medium
2/16/2018	JPMorgan Chase & Co.	Set Target	Buy	$53.00	Low
1/25/2018	Susquehanna Bancshares	Reiterated Rating	Positive ➝ Positive	$47.00 ➝ $55.00	Low
1/24/2018	Deutsche Bank Aktiengesellschaft	Set Target	Buy	$50.00	Low
1/18/2018	Wells Fargo & Company	Set Target	Hold	$33.00 ➝ $43.00	Low
1/11/2018	The Goldman Sachs Group	Boost Target	Buy	$46.00 ➝ $52.00	High
1/4/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $58.00	High
1/2/2018	SVB Leerink	Initiated Coverage	Mkt Perform ➝ Market Perform	$44.00	Low
12/26/2017	Cantor Fitzgerald	Set Target	Hold	$41.00	Low
12/12/2017	Guggenheim	Initiated Coverage	Buy ➝ Buy	$59.00	Low
12/4/2017	UBS Group	Set Target	Buy	$46.00	Low
11/30/2017	Cantor Fitzgerald	Set Target	Hold	$34.00	Medium
11/7/2017	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$32.00 ➝ $37.00	N/A
10/31/2017	Cantor Fitzgerald	Set Target	Hold	$34.00	N/A
10/24/2017	Mizuho	Reiterated Rating	Buy	$37.00	N/A
10/20/2017	Royal Bank of Canada	Set Target	Hold	$32.00	N/A
10/6/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$44.00 ➝ $48.00	N/A
10/6/2017	Morgan Stanley	Boost Target	Equal Weight	$36.00 ➝ $39.00	N/A
10/5/2017	UBS Group	Reiterated Rating	Buy	$46.00	N/A
10/5/2017	Nomura Instinet	Reiterated Rating	Buy	$37.00	N/A
10/5/2017	Cowen	Reiterated Rating	Market Perform	$30.00 ➝ $36.00	N/A
10/4/2017	Citigroup	Set Target	Buy	$42.00	N/A
10/4/2017	Mizuho	Reiterated Rating	Buy	$37.00	N/A
10/4/2017	Wells Fargo & Company	Set Target	Hold	$30.00 ➝ $32.00	N/A
10/4/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$34.00	High
10/4/2017	BTIG Research	Boost Target	Buy ➝ Buy	$42.00 ➝ $45.00	High

(Data available from 10/1/2017 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
0 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/5/2022

1 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/4/2022

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/4/2022

0 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

6/3/2022

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/3/2022

3 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/2/2022

0 very positive mentions
9 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/1/2022

2 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/1/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

marketwatch.com
9/28/2022
Retropharyngeal Abscess Market Size Share Volume Trends Demand Forecast Report 2022-2028
finance.yahoo.com
9/27/2022
Trastuzumab Biosimilars Global Market Report 2022: Focus on Product Launches by Major Players Shaping Industry - Yahoo Finance
businesswire.com
9/19/2022
Worldwide Epinephrine Autoinjector Industry to 2028 - Featuring Pfizer, Mylan, Sanofi and Hospira Among Others - ResearchAndMarkets.com - Business Wire
businesswire.com
9/16/2022
WWE® Elects Michelle McKenna & JoEllen Lyons Dillon to Board of Directors - Business Wire
finance.yahoo.com
9/8/2022
Contract Research Organisations (CROs) Market Report 2022-2032 - Yahoo Finance

Very Positive

marketwatch.com
9/28/2022
Telmisartan Market Share, Size, Growth, Future Trends, Key Players and Industry Analysis 2022-2028
globenewswire.com
9/17/2022
Epinephrine Market to Reach USD 3.59 Billion by 2029 at a CAGR 12.2 % – Price Trends, Top Companies, Growth Rate, Regional Analysis, Challenges and Business Opportunities - Adroit Market Research - GlobeNewswire

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Today's Range

Now: N/A

50 Day Range

MA: $15.57

$14.37

$15.86

52 Week Range

Now: N/A

Volume

14,100,488 shs

Average Volume

6,488,034 shs

Market Capitalization

$8.59 billion

P/E Ratio

29.92

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Mylan?: The following Wall Street research analysts have issued stock ratings on Mylan in the last year:
View the latest analyst ratings for MYL.
What is the current price target for Mylan?: 0 Wall Street analysts have set twelve-month price targets for Mylan in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mylan in the next year.
View the latest price targets for MYL.
What is the current consensus analyst rating for Mylan?: Mylan currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MYL.
What other companies compete with Mylan?: Other companies that are similar to Mylan include Jazz Pharmaceuticals, Perrigo, Corcept Therapeutics, Horizon Therapeutics Public and Pacira BioSciences. Learn More about companies similar to Mylan.
How do I contact Mylan's investor relations team?: Mylan's physical mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company's listed phone number is 724-514-1800 and its investor relations email address is [email protected] The official website for Mylan is www.mylan.com. Learn More about contacing Mylan investor relations.

Mylan - MYL Stock Price Target and Predictions

Analyst Price Target for MYL

Current Consensus is N/A

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.40 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Mylan?

What is the current price target for Mylan?

What is the current consensus analyst rating for Mylan?

What other companies compete with Mylan?

How do I contact Mylan's investor relations team?